South African Tuberculosis Vaccine Initiative
10
0
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
10.0%
1 terminated/withdrawn out of 10 trials
87.5%
+1.0% vs industry average
0%
0 trials in Phase 3/4
29%
2 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b
Role: collaborator
Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence
Role: collaborator
Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates
Role: collaborator
MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa
Role: collaborator
Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion
Role: collaborator
The Correlate of Risk Targeted Intervention Study
Role: collaborator
Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults
Role: collaborator
Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa
Role: collaborator
A Phase II Study of H56:IC31 in Healthy Adolescents
Role: collaborator
Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers
Role: collaborator
All 10 trials loaded